FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Christopher Portier

Research Profile

Concepts & Ideas

Chemicals & Drugs

Living Beings

Procedures

Carcinogenicity Tests

Disorders

Occupations

Anatomy

Livers

Co-author Network

Publications

TOP 3
Amber Wise; L Zeise; R Thomas Zoeller; Daniel A Axelrad; Kathryn Z Guyton; Fred Parham; Christopher Portier; Tracey J Woodruff
Upstream adverse effects in risk assessment: a model of polychlorinated biphenyls, thyroid hormone disruption and neurological outcomes in humans.
Fred Parham; Christopher Portier; R Thomas Zoeller; Amber Wise; Daniel A Axelrad; Kathryn Z Guyton; L Zeise; Tracey J Woodruff
Adverse effects in risk assessment: modeling polychlorinated biphenyls and thyroid hormone disruption outcomes in animals and humans.
Fred Parham; Christopher P Austin; Ruili Huang; Noel Southall; Raymond Tice; Christopher Portier
Dose-response modeling of high-throughput screening data.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Christopher Portier (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Amber Wise; L Zeise; R Thomas Zoeller; Daniel A Axelrad; Kathryn Z Guyton; Fred Parham; Christopher Portier; Tracey J Woodruff
Upstream adverse effects in risk assessment: a model of polychlorinated biphenyls, thyroid hormone disruption and neurological outcomes in humans.
Environmental research 2012;117():90-9.
2012: Fred Parham; Christopher Portier; R Thomas Zoeller; Amber Wise; Daniel A Axelrad; Kathryn Z Guyton; L Zeise; Tracey J Woodruff
Adverse effects in risk assessment: modeling polychlorinated biphenyls and thyroid hormone disruption outcomes in animals and humans.
Environmental research 2012;116():74-84.
2009: Fred Parham; Christopher P Austin; Ruili Huang; Noel Southall; Raymond Tice; Christopher Portier
Dose-response modeling of high-throughput screening data.
Journal of biomolecular screening 2009;14(10):1216-27.
2009: Julia M Gohlke; Patricia Stockton; Stella Sieber; Julie Foley; Christopher Portier
AhR-mediated gene expression in the developing mouse telencephalon.
Reproductive toxicology (Elmsford, N.Y.) 2009;28(3):321-8.
2009: Andrea S Prause; Michael H Stoffel; Christopher Portier; Meike Mevissen
Expression and function of 5-HT7 receptors in smooth muscle preparations from equine duodenum, ileum, and pelvic flexure.
Research in veterinary science 2009;87(2):292-9.
2009: Christopher Portier
4 Toxicological decision-making on hazards and risks - status quo and way forward: 4.1 current concepts and schemes of science-driven toxicological decision-making - an overview.
Human & experimental toxicology 2009;28(2-3):123-5.
2009: Marjolein V Smith; Windy A Boyd; Grace E Kissling; Julie R Rice; Daniel W Snyder; Christopher Portier; Jonathan H Freedman
A discrete time model for the analysis of medium-throughput C. elegans growth data.
PloS one 2009;4(9):e7018.
2009: Windy A Boyd; Marjolein V Smith; Grace E Kissling; Julie R Rice; Daniel W Snyder; Christopher Portier; Jonathan H Freedman
Application of a mathematical model to describe the effects of chlorpyrifos on Caenorhabditis elegans development.
PloS one 2009;4(9):e7024.
2009: Julia M Gohlke; Reuben Thomas; Yonqing Zhang; Michael C Rosenstein; Allan Peter Davis; Cynthia Murphy; Kevin G Becker; Carolyn J Mattingly; Christopher Portier
Genetic and environmental pathways to complex diseases.
BMC systems biology 2009;3():46.
2009: Reuben Thomas; Julia M Gohlke; Geffrey F Stopper; Frederick M Parham; Christopher Portier
Choosing the right path: enhancement of biologically relevant sets of genes or proteins using pathway structure.
Genome biology 2009;10(4):R44.
2008: A Schmitz; Christopher Portier; Wolfgang Thormann; Regula Theurillat; Meike Mevissen
Stereoselective biotransformation of ketamine in equine liver and lung microsomes.
Journal of veterinary pharmacology and therapeutics 2008;31(5):446-55.
2008: Ravi P Subramaniam; Chao Chen; Kenny S Crump; Danielle Devoney; John F Fox; Christopher Portier; Paul M Schlosser; Chad M Thompson; Paul White
Uncertainties in biologically-based modeling of formaldehyde-induced respiratory cancer risk: identification of key issues.
Risk analysis : an official publication of the Society for Risk Analysis 2008;28(4):907-23.
2008: Julia M Gohlke; Sharon H Hrynkow; Christopher Portier
Health, economy, and environment: sustainable energy choices for a nation.
Environmental health perspectives 2008;116(6):A236-7.
2008: M Buehler; Adrian Steiner; Mireille Meylan; Christopher Portier; Meike Mevissen
In vitro effects of bethanechol on smooth muscle preparations from abomasal fundus, corpus, and antrum of dairy cows.
Research in veterinary science 2008;84(3):444-51.
2008: Grace E Kissling; Christopher Portier; James Huff
MtBE and cancer in animals: statistical issues with poly-3 survival adjustments for lifetime studies.
Regulatory toxicology and pharmacology : RTP 2008;50(3):428-9.
2008: Menghang Xia; Ruili Huang; Kristine L Witt; Noel Southall; Jennifer Fostel; Ming-Hsuang Cho; Ajit Jadhav; Cynthia S Smith; James Inglese; Christopher Portier; Raymond R Tice; Christopher P Austin
Compound cytotoxicity profiling using quantitative high-throughput screening.
Environmental health perspectives 2008;116(3):284-91.
2008: Julia M Gohlke; Olivier Armant; Frederick M Parham; Marjolein V Smith; Celine Zimmer; Diogo S Castro; Laurent Nguyen; Joel Parker; Gérard Gradwohl; Christopher Portier; François Guillemot
Characterization of the proneural gene regulatory network during mouse telencephalon development.
BMC biology 2008;6():15.
2007: Hugh A Barton; Weihsueh A Chiu; R Woodrow Setzer; Melvin E Andersen; A John Bailer; Frederic Yves Bois; Robert S DeWoskin; Sean Hays; Gunnar Johanson; Nancy Jones; George D Loizou; Robert C Macphail; Christopher Portier; Martin Spendiff; Yu-Mei Tan
Characterizing uncertainty and variability in physiologically based pharmacokinetic models: state of the science and needs for research and implementation.
Toxicological sciences : an official journal of the Society of Toxicology 2007;99(2):395-402.
2007: Julia M Gohlke; Christopher Portier
The forest for the trees: a systems approach to human health research.
Environmental health perspectives 2007;115(9):1261-3.
2007: Julia B R Pfeiffer; Meike Mevissen; Adrian Steiner; Christopher Portier; Mireille Meylan
In vitro effects of bethanechol on specimens of intestinal smooth muscle obtained from the duodenum and jejunum of healthy dairy cows.
American journal of veterinary research 2007;68(3):313-22.
2007: Marjo V Smith; Chris R Miller; Michael Kohn; Nigel J Walker; Christopher Portier
Absolute estimation of initial concentrations of amplicon in a real-time RT-PCR process.
BMC bioinformatics 2007;8():409.
2006: Monika Knobloch; Christopher Portier; Olivier L Levionnois; Regula Theurillat; Wolfgang Thormann; Claudia Spadavecchia; Meike Mevissen
Antinociceptive effects, metabolism and disposition of ketamine in ponies under target-controlled drug infusion.
Toxicology and applied pharmacology 2006;216(3):373-86.
2006: Richard A Becker; Christopher J Borgert; Simon Webb; Jay Ansell; Sara Amundson; Christopher Portier; Alan M Goldberg; Leon H Bruner; Andrew Rowan; rodger curren; William T Stott
Report of an ISRTP workshop: progress and barriers to incorporating alternative toxicological methods in the U.S.
Regulatory toxicology and pharmacology : RTP 2006;46(1):18-22.
2006: Hiroyoshi Toyoshiba; Hideko Sone; Takeharu Yamanaka; Frederick M Parham; Richard D Irwin; Gary A Boorman; Christopher Portier
Gene interaction network analysis suggests differences between high and low doses of acetaminophen.
Toxicology and applied pharmacology 2006;215(3):306-16.
2005: David B Resnik; Christopher Portier
Pesticide testing on human subjects: weighing benefits and risks.
Environmental health perspectives 2005;113(7):813-7.
2005: Christopher Portier; David A Schwartz
The NIEHS and the National Toxicology Program: an integrated scientific vision.
Environmental health perspectives 2005;113(7):A440.
2005: Gary A Boorman; Richard D Irwin; Molly K Vallant; Diane K Gerken; Edward K Lobenhofer; milton hejtmancik; Patrick Hurban; April Brys; Gregory S Travlos; Joel Parker; Christopher Portier
Variation in the hepatic gene expression in individual male Fischer rats.
Toxicologic pathology 2005;33(1):102-10.
2005: Nigel J Walker; Patrick W Crockett; Abraham Nyska; Amy E Brix; Micheal P Jokinen; Donald M Sells; James R Hailey; Micheal Easterling; Joseph K Haseman; Ming Yin; Michael E Wyde; John R Bucher; Christopher Portier
Dose-additive carcinogenicity of a defined mixture of "dioxin-like compounds".
Environmental health perspectives 2005;113(1):43-8.
2004: John R Bucher; Christopher Portier
Human carcinogenic risk evaluation, Part V: The national toxicology program vision for assessing the human carcinogenic hazard of chemicals.
Toxicological sciences : an official journal of the Society of Toxicology 2004;82(2):363-6.
2004: Dori R Germolec; Michael Kashon; Abraham Nyska; frieke kuper; Christopher Portier; C Kommineni; K A Johnson; Michael I Luster
The accuracy of extended histopathology to detect immunotoxic chemicals.
Toxicological sciences : an official journal of the Society of Toxicology 2004;82(2):504-14.
2004: Takeharu Yamanaka; Hiroyoshi Toyoshiba; Hideko Sone; Frederick M Parham; Christopher Portier
The TAO-Gen algorithm for identifying gene interaction networks with application to SOS repair in E. coli.
Environmental health perspectives 2004;112(16):1614-21.
2004: Hiroyoshi Toyoshiba; Takeharu Yamanaka; Hideko Sone; Frederick M Parham; Nigel J Walker; Jeanelle Martinez; Christopher Portier
Gene interaction network suggests dioxin induces a significant linkage between aryl hydrocarbon receptor and retinoic acid receptor beta.
Environmental health perspectives 2004;112(12):1217-24.
2004: Arnold Schecter; George W Lucier; Michael L Cunningham; Kamal M Abdo; Greg Blumenthal; Andrew G Silver; Ron Melnick; Christopher Portier; Dana B Barr; John R Barr; Stephen B Stanfill; Donald G Patterson; Larry L Needham; Woodhall Stopford; Scott A Masten; Jill Mignogna; Kuang Chi Tung
Human consumption of methyleugenol and its elimination from serum.
Environmental health perspectives 2004;112(6):678-80.
2004: Michael D Shelby; Christopher Portier; Lynn Rose Goldman; John Moore; Annette Iannucci; Gloria D Jahnke; Steve Donkin
NTP-CERHR expert panel report on the reproductive and developmental toxicity of methanol.
Reproductive toxicology (Elmsford, N.Y.) 2004;18(3):303-90.
2004: Dori R Germolec; Abraham Nyska; Michael Kashon; frieke kuper; Christopher Portier; C Kommineni; K A Johnson; Michael I Luster
Extended histopathology in immunotoxicity testing: interlaboratory validation studies.
Toxicological sciences : an official journal of the Society of Toxicology 2004;78(1):107-15.
2004: D Trachsel; Peter Tschudi; Christopher Portier; M Kuhn; Wolfgang Thormann; Günter Scholtysik; Meike Mevissen
Pharmacokinetics and pharmacodynamic effects of amiodarone in plasma of ponies after single intravenous administration.
Toxicology and applied pharmacology 2004;195(1):113-25.
2004: Hiroyoshi Toyoshiba; Nigel J Walker; A John Bailer; Christopher Portier
Evaluation of toxic equivalency factors for induction of cytochromes P450 CYP1A1 and CYP1A2 enzyme activity by dioxin-like compounds.
Toxicology and applied pharmacology 2004;194(2):156-68.
2003: Rajendra S Chhabra; John R Bucher; Mary Wolfe; Christopher Portier
Toxicity characterization of environmental chemicals by the US National Toxicology Program: an overview.
International journal of hygiene and environmental health 2003;206(4-5):437-45.
2003: Petra J M Koken; Warren T Piver; Frank Ye; Anne Elixhauser; Lola M Olsen; Christopher Portier
Temperature, air pollution, and hospitalization for cardiovascular diseases among elderly people in Denver.
Environmental health perspectives 2003;111(10):1312-7.
2003: Shree Y Whitaker; Hien T Tran; Christopher Portier
Development of a biologically-based controlled growth and differentiation model for developmental toxicology.
Journal of mathematical biology 2003;46(1):1-16.
2002: Amy H Kim; Michael C Kohn; Christopher Portier; Nigel J Walker
Impact of physiologically based pharmacokinetic modeling on benchmark dose calculations for TCDD-induced biochemical responses.
Regulatory toxicology and pharmacology : RTP 2002;36(3):287-96.
2002: Ruth Weiss; Meike Mevissen; Daniela S Hauser; Günter Scholtysik; Christopher Portier; Bernhard Walter; Urs E Studer; Hansjörg Danuser
Inhibition of human and pig ureter motility in vitro and in vivo by the K(+) channel openers PKF 217-744b and nicorandil.
The Journal of pharmacology and experimental therapeutics 2002;302(2):651-8.
2002: Christopher Portier
Comments on the International Symposium on Light, Endocrine Systems and Cancer.
Neuro endocrinology letters 2002;23 Suppl 2():79-81.
2002: Christopher Portier
Endocrine dismodulation and cancer.
Neuro endocrinology letters 2002;23 Suppl 2():43-7.
2002: Frederick M Parham; HB Matthews; Christopher Portier
A physiologically based pharmacokinetic model of p,p'-dichlorodiphenylsulfone.
Toxicology and applied pharmacology 2002;181(3):153-63.
2002: P Trinia Simmons; Christopher Portier
Toxicogenomics: the new frontier in risk analysis.
Carcinogenesis 2002;23(6):903-5.
2002: Michael C Kohn; Ronald L Melnick; Frank Ye; Christopher Portier
Pharmacokinetics of sodium nitrite-induced methemoglobinemia in the rat.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(6):676-83.
2002: Jung-Wan Koo; Frederick M Parham; Michael C Kohn; Scott A Masten; John W Brock; Larry L Needham; Christopher Portier
The association between biomarker-based exposure estimates for phthalates and demographic factors in a human reference population.
Environmental health perspectives 2002;110(4):405-10.
2002: D S Hauser; Meike Mevissen; R Weiss; Christopher Portier; Günter Scholtysik; Urs E Studer; Hansjörg Danuser
Effects of ketanserin and DOI on spontaneous and 5-HT-evoked peristalsis of the pig ureter in vivo.
British journal of pharmacology 2002;135(4):1026-32.
2001: B A Willems; Ronald L Melnick; Michael C Kohn; Christopher Portier
A physiologically based pharmacokinetic model for inhalation and intravenous administration of naphthalene in rats and mice.
Toxicology and applied pharmacology 2001;176(2):81-91.
2001: Michael C Kohn; Nigel J Walker; Amy H Kim; Christopher Portier
Physiological modeling of a proposed mechanism of enzyme induction by TCDD.
Toxicology 2001;162(3):193-208.
2001: Christopher Portier
Linking toxicology and epidemiology: the role of mechanistic modelling.
Statistics in medicine 2001;20(9-10):1387-93.
2001: Meike Mevissen; Helena Denac; A Schaad; Christopher Portier; Günter Scholtysik
Identification of a cardiac sodium channel insensitive to synthetic modulators.
Journal of cardiovascular pharmacology and therapeutics 2001;6(2):201-12.
2001: Frank Ye; Warren T Piver; M Ando; Christopher Portier
Effects of temperature and air pollutants on cardiovascular and respiratory diseases for males and females older than 65 years of age in Tokyo, July and August 1980-1995.
Environmental health perspectives 2001;109(4):355-9.
2000: AM Tritscher; J Mahler; Christopher Portier; George W Lucier; Nigel J Walker
Induction of lung lesions in female rats following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Toxicologic pathology 2000;28(6):761-9.
2000: Christopher Portier; Frederick M Parham
Comments on a biochemical model of cyclophosphamide hematotoxicity.
Journal of toxicology and environmental health. Part A 2000;61(5-6):525-8.
2000: N C Halmes; Stephen M Roberts; J Keith Tolson; Christopher Portier
Reevaluating cancer risk estimates for short-term exposure scenarios.
Toxicological sciences : an official journal of the Society of Toxicology 2000;58(1):32-42.
2000: Michael C Kohn; Frederick M Parham; Scott A Masten; Christopher Portier; M D Shelby; John W Brock; Larry L Needham
Human exposure estimates for phthalates.
Environmental health perspectives 2000;108(10):A440-2.
2000: Christopher Portier
Risk ranges for various endpoints following exposure to 2,3,7,8-TCDD.
Food additives and contaminants 2000;17(4):335-46.
2000: Nigel J Walker; AM Tritscher; Robert C Sills; George W Lucier; Christopher Portier
Hepatocarcinogenesis in female Sprague-Dawley rats following discontinuous treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Toxicological sciences : an official journal of the Society of Toxicology 2000;54(2):330-7.
2000: C D Sherman; Christopher Portier
Calculation of the cumulative distribution function of the time to a small observable tumor.
Bulletin of mathematical biology 2000;62(2):229-40.
2000: M V Smith; Christopher Portier
Incorporating observability thresholds of tumors into the two-stage carcinogenesis model.
Mathematical biosciences 2000;163(1):75-89.
1999: Warren T Piver; M Ando; Frank Ye; Christopher Portier
Temperature and air pollution as risk factors for heat stroke in Tokyo, July and August 1980-1995.
Environmental health perspectives 1999;107(11):911-6.
1999: HA el Masri; D A Bell; Christopher Portier
Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans.
Toxicology and applied pharmacology 1999;158(3):221-30.
1999: Melvin Andersen; Rory B Conolly; E M Faustman; Robert Kavlock; Christopher Portier; D M Sheehan; P J Wier; L Ziese
Quantitative mechanistically based dose-response modeling with endocrine-active compounds.
Environmental health perspectives 1999;107 Suppl 4():631-8.
1999: Ronald L Melnick; Robert C Sills; Christopher Portier; Joseph H Roycroft; Billy J Chou; Sondra L Grumbein; Rodney A Miller
Multiple organ carcinogenicity of inhaled chloroprene (2-chloro-1,3-butadiene) in F344/N rats and B6C3F1 mice and comparison of dose-response with 1,3-butadiene in mice.
Carcinogenesis 1999;20(5):867-78.
1999: HA el Masri; Christopher Portier
Replication potential of cells via the protein kinase C-MAPK pathway: application of a mathematical model.
Bulletin of mathematical biology 1999;61(2):379-98.
1999: Nigel J Walker; Christopher Portier; S F Lax; FG Crofts; Yu Li; George W Lucier; Thomas R Sutter
Characterization of the dose-response of CYP1B1, CYP1A1, and CYP1A2 in the liver of female Sprague-Dawley rats following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Toxicology and applied pharmacology 1999;154(3):279-86.
1998: Christopher Portier; Douglas A Bell
Genetic susceptibility: significance in risk assessment.
Toxicology letters 1998;102-103():185-9.
1998: Christopher Portier; F Ye
U-shaped dose-response curves for carcinogens.
Human & experimental toxicology 1998;17(12):705-7; discussion 716-8.
1998: C D Sherman; Christopher Portier
Eyes closed: simple, intuitive, statistically sound, and efficient methods for estimating parameters of clonal growth cancer models.
Risk analysis : an official publication of the Society for Risk Analysis 1998;18(5):529-34.
1998: Frederick M Parham; Christopher Portier
Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls. II. Rates of metabolism.
Toxicology and applied pharmacology 1998;151(1):110-6.
1998: HA el Masri; Christopher Portier
Physiologically based pharmacokinetics model of primidone and its metabolites phenobarbital and phenylethylmalonamide in humans, rats, and mice.
Drug metabolism and disposition: the biological fate of chemicals 1998;26(6):585-94.
1998: J A Murrell; Christopher Portier; R W Morris
Characterizing dose-response: I: Critical assessment of the benchmark dose concept.
Risk analysis : an official publication of the Society for Risk Analysis 1998;18(1):13-26.
1997: G M Blumenthal; Michael C Kohn; Christopher Portier
A mathematical model of production, distribution, and metabolism of melatonin in mammalian systems.
Toxicology and applied pharmacology 1997;147(1):83-92.
1997: C D Sherman; Christopher Portier
The two-stage model of carcinogenesis: overcoming the nonidentifiability dilemma.
Risk analysis : an official publication of the Society for Risk Analysis 1997;17(3):367-74.
1997: Frederick M Parham; Michael C Kohn; HB Matthews; C DeRosa; Christopher Portier
Using structural information to create physiologically based pharmacokinetic models for all polychlorinated biphenyls.
Toxicology and applied pharmacology 1997;144(2):340-7.
1997: Kevin W Gaido; LS Leonard; S Lovell; J C Gould; D Babaï; Christopher Portier; Donald P McDonnell
Evaluation of chemicals with endocrine modulating activity in a yeast-based steroid hormone receptor gene transcription assay.
Toxicology and applied pharmacology 1997;143(1):205-12.
1996: Christopher Portier; CM Lyles
Practicing safe modeling: GLP for biologically based mechanistic models.
Environmental health perspectives 1996;104(8):806.
1996: Christopher Portier; Annette Kopp-Schneider; C D Sherman
Calculating tumor incidence rates in stochastic models of carcinogenesis.
Mathematical biosciences 1996;135(2):129-46.
1996: John R Bucher; Christopher Portier; J I Goodman; E M Faustman; George W Lucier
Workshop overview. National Toxicology Program Studies: principles of dose selection and applications to mechanistic based risk assessment.
Fundamental and applied toxicology : official journal of the Society of Toxicology 1996;31(1):1-8.
1996: C D Sherman; Christopher Portier
Stochastic simulation of a multistage model of carcinogenesis.
Mathematical biosciences 1996;134(1):35-50.
1996: Christopher Portier; C D Sherman; M Kohn; L Edler; Annette Kopp-Schneider; R M Maronpot; George W Lucier
Modeling the number and size of hepatic focal lesions following exposure to 2,3,7,8-TCDD.
Toxicology and applied pharmacology 1996;138(1):20-30.
1996: Ronald L Melnick; Michael C Kohn; Christopher Portier
Implications for risk assessment of suggested nongenotoxic mechanisms of chemical carcinogenesis.
Environmental health perspectives 1996;104 Suppl 1():123-34.
1996: J R Buchanan; Christopher Portier
The use of data on biologically reactive intermediates in risk assessment.
Advances in experimental medicine and biology 1996;387():429-37.
1996: Michael C Kohn; C H Sewall; George W Lucier; Christopher Portier
A mechanistic model of effects of dioxin on thyroid hormones in the rat.
Toxicology and applied pharmacology 1996;136(1):29-48.
1995: C D Sherman; Christopher Portier
Quantitative analysis of multiple phenotype enzyme-altered foci in rat hepatocarcinogenesis experiments: the multipath/multistage model.
Carcinogenesis 1995;16(10):2499-506.
1995: Annette Kopp-Schneider; Christopher Portier
Carcinoma formation in NMRI mouse skin painting studies is a process suggesting greater than two stages.
Carcinogenesis 1995;16(1):53-9.
1994: Michael C Kohn; George W Lucier; Christopher Portier
The importance of biological realism in dioxin risk assessment models.
Risk analysis : an official publication of the Society for Risk Analysis 1994;14(6):993-1000.
1994: Annette Kopp-Schneider; Christopher Portier; C D Sherman
The exact formula for tumor incidence in the two-stage model.
Risk analysis : an official publication of the Society for Risk Analysis 1994;14(6):1079-80.
1994: C D Sherman; Christopher Portier; Annette Kopp-Schneider
Multistage models of carcinogenesis: an approximation for the size and number distribution of late-stage clones.
Risk analysis : an official publication of the Society for Risk Analysis 1994;14(6):1039-48.
1994: Christopher Portier; G W Lucier; L Edler
Risk from low-dose exposures.
Science (New York, N.Y.) 1994;266(5188):1141-2.
1994: Michael I Luster; Christopher Portier; D G Pait; Dori R Germolec
The use of animal tests in risk assessment for immunotoxicology.
Toxicology in vitro : an international journal published in association with BIBRA 1994;8(5):945-50.
1994: Annette Kopp-Schneider; Christopher Portier
A stem cell model for carcinogenesis.
Mathematical biosciences 1994;120(2):211-32.
1994: Christopher Portier
Biostatistical issues in the design and analysis of animal carcinogenicity experiments.
Environmental health perspectives 1994;102 Suppl 1():5-8.
1994: David G Hoel; Christopher Portier
Nonlinearity of dose-response functions for carcinogenicity.
Environmental health perspectives 1994;102 Suppl 1():109-13.
1994: Michael C Kohn; Christopher Portier
A model of effects of TCDD on expression of rat liver proteins.
Progress in clinical and biological research 1994;387():211-22.
1993: Christopher Portier; Annette Kopp-Schneider; C D Sherman
Using cell replication data in mathematical modeling in carcinogenesis.
Environmental health perspectives 1993;101 Suppl 5():79-86.
1993: Ronald L Melnick; James Huff; J Carl Barrett; Robert R Maronpot; George W Lucier; Christopher Portier
Cell proliferation and chemical carcinogenesis: symposium overview.
Environmental health perspectives 1993;101 Suppl 5():3-7.
1993: Michael C Kohn; Christopher Portier
Effects of the mechanism of receptor-mediated gene expression on the shape of the dose-response curve.
Risk analysis : an official publication of the Society for Risk Analysis 1993;13(5):565-72.
1993: K L Meier; A John Bailer; Christopher Portier
A measure of tumorigenic potency incorporating dose-response shape.
Biometrics 1993;49(3):917-26.
1993: G J Carr; Christopher Portier
An evaluation of some methods for fitting dose-response models to quantal-response developmental toxicology data.
Biometrics 1993;49(3):779-91.
1993: A John Bailer; Christopher Portier
An index of tumorigenic potency.
Biometrics 1993;49(2):357-65.
1993: Michael C Kohn; George W Lucier; G C Clark; C Sewall; A M Tritscher; Christopher Portier
A mechanistic model of effects of dioxin on gene expression in the rat liver.
Toxicology and applied pharmacology 1993;120(1):138-54.
1993: George W Lucier; Christopher Portier; M A Gallo
Receptor mechanisms and dose-response models for the effects of dioxins.
Environmental health perspectives 1993;101(1):36-44.
1993: R L Melnick; J Huff; J C Barrett; Robert R Maronpot; George W Lucier; Christopher Portier
Cell proliferation and chemical carcinogenesis: a symposium overview.
Molecular carcinogenesis 1993;7(3):135-8.
1993: Christopher Portier
Mechanistic modelling and risk assessment.
Pharmacology & toxicology 1993;72 Suppl 1():28-32.
1992: A M Tritscher; Joyce A Goldstein; Christopher Portier; Z McCoy; G C Clark; George W Lucier
Dose-response relationships for chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin in a rat tumor promotion model: quantification and immunolocalization of CYP1A1 and CYP1A2 in the liver.
Cancer research 1992;52(12):3436-42.
1992: Annette Kopp-Schneider; Christopher Portier
Birth and death/differentiation rates of papillomas in mouse skin.
Carcinogenesis 1992;13(6):973-8.
1992: Walter W Piegorsch; G J Carr; Christopher Portier; David G Hoel
Concordance of carcinogenic response between rodent species: potency dependence and potential underestimation.
Risk analysis : an official publication of the Society for Risk Analysis 1992;12(1):115-21.
1991: Annette Kopp-Schneider; Christopher Portier
Distinguishing between models of carcinogenesis: the role of clonal expansion.
Fundamental and applied toxicology : official journal of the Society of Toxicology 1991;17(3):601-13.
1991: Christopher Portier; Annette Kopp-Schneider
A multistage model of carcinogenesis incorporating DNA damage and repair.
Risk analysis : an official publication of the Society for Risk Analysis 1991;11(3):535-43.
1991: Annette Kopp-Schneider; Christopher Portier; Friedrich Rippmann
The application of a multistage model that incorporates DNA damage and repair to the analysis of initiation/promotion experiments.
Mathematical biosciences 1991;105(2):139-66.
1991: Walter J Rogan; P J Blanton; Christopher Portier; E Stallard
Should the presence of carcinogens in breast milk discourage breast feeding?
Regulatory toxicology and pharmacology : RTP 1991;13(3):228-40.
1991: G J Carr; Christopher Portier
An evaluation of the Rai and Van Ryzin dose-response model in teratology.
Risk analysis : an official publication of the Society for Risk Analysis 1991;11(1):111-20.
1990: A John Bailer; Christopher Portier
A note on fitting one-compartment models: non-linear least squares versus linear least squares using transformed data.
Journal of applied toxicology : JAT 1990;10(4):303-6.
1990: Christopher Portier; L Edler
Two-stage models of carcinogenesis, classification of agents, and design of experiments.
Fundamental and applied toxicology : official journal of the Society of Toxicology 1990;14(3):444-60.
1990: Christopher Portier; David G Hoel; Norman L Kaplan; A Kopp
Biologically based models for risk assessment.
IARC scientific publications 1990;(104):20-8.
1989: A Kopp; Christopher Portier
A note on approximating the cumulative distribution function of the time to tumor onset in multistage models.
Biometrics 1989;45(4):1259-63.
1989: Christopher Portier; Norman L Kaplan
Variability of safe dose estimates when using complicated models of the carcinogenic process. A case study: methylene chloride.
Fundamental and applied toxicology : official journal of the Society of Toxicology 1989;13(3):533-44.
1989: Christopher Portier; A John Bailer
Testing for increased carcinogenicity using a survival-adjusted quantal response test.
Fundamental and applied toxicology : official journal of the Society of Toxicology 1989;12(4):731-7.
1989: Christopher Portier; A John Bailer
Two-stage models of tumor incidence for historical control animals in the National Toxicology Program's carcinogenicity experiments.
Journal of toxicology and environmental health 1989;27(1):21-45.
1988: Christopher Portier
Species correlation of chemical carcinogens.
Risk analysis : an official publication of the Society for Risk Analysis 1988;8(4):551-3.
1988: A John Bailer; Christopher Portier
Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples.
Biometrics 1988;44(2):417-31.
1988: A John Bailer; Christopher Portier
An illustration of dangers of ignoring survival differences in carcinogenic data.
Journal of applied toxicology : JAT 1988;8(3):185-9.
1987: Christopher Portier
Statistical properties of a two-stage model of carcinogenesis.
Environmental health perspectives 1987;76():125-31.
1987: Christopher Portier; David G Hoel
Issues concerning the estimation of the TD50.
Risk analysis : an official publication of the Society for Risk Analysis 1987;7(4):437-47.
1987: Christopher Portier; A John Bailer
Simulating failure times when the event of interest is unobservable with emphasis on animal carcinogenicity studies.
Computers and biomedical research, an international journal 1987;20(5):458-66.
1987: Christopher Portier; G E Dinse
Semiparametric analysis of tumor incidence rates in survival/sacrifice experiments.
Biometrics 1987;43(1):107-14.
1986: Christopher Portier; J C Hedges; David G Hoel
Age-specific models of mortality and tumor onset for historical control animals in the National Toxicology Program's carcinogenicity experiments.
Cancer research 1986;46(9):4372-8.
1986: Christopher Portier
Type 1 error and power of the linear trend test in proportions under the National Toxicology Program's modified pathology protocol.
Fundamental and applied toxicology : official journal of the Society of Toxicology 1986;6(3):515-9.
1984: Christopher Portier; David G Hoel
Design of animal carcinogenicity studies for goodness-of-fit of multistage models.
Fundamental and applied toxicology : official journal of the Society of Toxicology 1984;4(6):949-59.